Royce & Associates LP Buys 302,399 Shares of ADMA Biologics Inc $ADMA

Royce & Associates LP lifted its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 32.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 1,234,467 shares of the biotechnology company’s stock after acquiring an additional 302,399 shares during the quarter. Royce & Associates LP’s holdings in ADMA Biologics were worth $22,517,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in ADMA. State Street Corp increased its holdings in ADMA Biologics by 5.6% in the second quarter. State Street Corp now owns 12,078,505 shares of the biotechnology company’s stock worth $219,950,000 after purchasing an additional 637,727 shares in the last quarter. Westfield Capital Management Co. LP bought a new stake in ADMA Biologics in the third quarter worth approximately $74,866,000. Dimensional Fund Advisors LP increased its holdings in ADMA Biologics by 0.7% in the third quarter. Dimensional Fund Advisors LP now owns 4,798,274 shares of the biotechnology company’s stock worth $70,343,000 after purchasing an additional 35,199 shares in the last quarter. American Century Companies Inc. increased its holdings in ADMA Biologics by 1.8% in the third quarter. American Century Companies Inc. now owns 4,695,923 shares of the biotechnology company’s stock worth $68,842,000 after purchasing an additional 84,934 shares in the last quarter. Finally, UBS Group AG increased its holdings in ADMA Biologics by 129.9% in the fourth quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company’s stock worth $83,345,000 after purchasing an additional 2,581,670 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Trading Down 1.1%

Shares of ADMA Biologics stock opened at $8.15 on Wednesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95. ADMA Biologics Inc has a 52 week low of $7.21 and a 52 week high of $22.37. The stock has a 50 day moving average price of $10.20 and a two-hundred day moving average price of $14.84. The stock has a market capitalization of $1.89 billion, a PE ratio of 11.99 and a beta of 0.83.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, meeting analysts’ consensus estimates of $0.19. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The firm had revenue of $114.49 million during the quarter, compared to analysts’ expectations of $139.98 million. During the same quarter last year, the firm posted $0.11 earnings per share. The company’s revenue for the quarter was down .3% compared to the same quarter last year. As a group, equities analysts anticipate that ADMA Biologics Inc will post 0.84 earnings per share for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In other news, Director Jerrold B. Grossman acquired 12,500 shares of ADMA Biologics stock in a transaction on Monday, May 11th. The stock was purchased at an average price of $8.01 per share, with a total value of $100,125.00. Following the completion of the purchase, the director owned 513,884 shares of the company’s stock, valued at approximately $4,116,210.84. The trade was a 2.49% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the sale, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at $7,292,958. This trade represents a 2.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 3.90% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Zacks Research downgraded ADMA Biologics from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Mizuho lowered their target price on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Canaccord Genuity Group lowered their target price on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Finally, Wall Street Zen downgraded ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, ADMA Biologics has a consensus rating of “Hold” and an average target price of $19.00.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.